Back
Metagenomi Therapeutics, Inc. 10K Form
Sell
26
MGX
Metagenomi Therapeutics, Inc.
Last Price:
$1.46
Seasonality Move:
-34.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MGX News And Ratings
See the #1 stock for the next 7 days that we like better than MGX
MGX Financial Statistics
Sales & Book Value
| Annual Sales: | $52.3M |
|---|---|
| Cash Flow: | $-21.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.75 |
| Price / Book: | 0.31 |
Profitability
| EPS (TTM): | -2.38350 |
|---|---|
| Net Income (TTM): | $-88.7M |
| Gross Margin: | $46.9M |
| Return on Equity: | -41.18% |
| Return on Assets: | -29.56% |
Metagenomi Therapeutics, Inc. Earnings Forecast
Key Metagenomi Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 4 years for MGX is 89.66%.
-
The Selling, General & Administrative Expenses for MGX have been equal to 61.22% of Gross Profit Margin.
-
The Research & Development expenses have been 208.78% of Revenue.
-
The Net Earning history of MGX is -149.26% of Total Revenues.
-
Per Share Earnings over the last 4 years have been positive in 0 years.
Metagenomi Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | MGX |
| Website: | metagenomi.co |
Debt
| Debt-to-Equity Ratio: | 0.23 |
|---|---|
| Current Ratio: | 6.42 |
| Quick Ratio: | 6.26 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
MGX Technical Analysis vs Fundamental Analysis
Sell
26
Metagenomi Therapeutics, Inc. (MGX)
is a Sell
Is Metagenomi Therapeutics, Inc. a Buy or a Sell?
-
Metagenomi Therapeutics, Inc. stock is rated a SellThe current Metagenomi Therapeutics, Inc. [MGX] share price is $1.45. The Score for MGX is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.